Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy

Chinese Medical Journal

Volumn 123, Issue 24, 2010, Pages 3587-3590

  Li, Zai Cun ^a   Li, Hong Jun ^a   Dai, Li Li ^a   Gao, Yan Qing ^a   Cai, Wei Ping ^b   Li, Hai Ying ^a   Huang, Xiao Jie ^a   Zhang, Tong ^a   Wu, Hao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Guangzhou Eighth People's Hospital   (China)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Liver injury; Non nucleosides reverse transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHINA; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG-INDUCED LIVER INJURY; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78650587967     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.24.016     Document Type: Article

References (26)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
2. Roger JP, David LH. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-873.
3. Kontorinis N, Dieterich DT. Toxicity of nonnucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 173-182.
4. Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 167-172.
5. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23: 183-194.
6. Clark S, Creighton S, Portmann B, Taylor C, Wendon J, Cramp M. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002; 36: 295-301.
7. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. Morb Mortal Wkly Rep 2001; 49: 1153-1156.
8. Benn P, Mercey D, Brink N, Scott G, Williams I. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357: 687-688.
9. Division of AIDS, National Institute of Allergy and Infection. Table for grading the severity of adult and pediatric adverse events, 2004. (Accessed at http://rcc.tech-res.com/tox_tables.htm.)
10. Brinkman K, ter Hofstede H, Burger D, Smeitink J, Koopmans P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.
11. Nunez M, Lana R, Mendoza J, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of HAART. J Acquir Immune Def Syndr 2001; 27: 426-431.
12. D'Arminio Monforte A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-123.
13. ter Hofstede H, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11: 611-616.
14. Gisolf E, Dreezen C, Danner S, Weel JL, Weverling GJ; Prometheus Study Group. Risk factors for liver injury in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Promethius Study Group. Clin Infect Dis 2000; 3: 1234-1239.
15. Walker U, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-2173.
16. De Maat M, Mathot R, Veldkamp A, Huitma AD, Mulder JW, Meenhorst PL, et al. Hepatotoxicity following nevirapine containing regimens in HIV-1-infected individuals. Pharmacol Res 2002; 46: 295-300.
17. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 (Suppl 2): s90-s97.
18. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98: 12671-12676.
19. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1): s21-s33.
20. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538-539.
21. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
22. + T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicenter study. Chin Med J 2009; 122: 2497-2502.
23. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, et al. Risk factors for liver injury in patients treated with highly active antiretroviral therapy. J Acquir Immune Def Syndr 2001; 27: 316-318.
24. Aceti A, Pasquazzi C, Zechini B, De Bac C; The LIVER HAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-48.
25. Wit F, Weverling G, Weel J, Jurrians S, Lange J. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
26. Dong PL, Li ZC, Zhang K. Analysis of 144 HIV/AIDS patients coinfected with HCV and/or HBV. China Public Health (Chin) 2003; 19: 866.